Wall Street is positive on C4 Therapeutics Inc (CCCC). On average, analysts give C4 Therapeutics Inc a Buy rating. The average price target is $15.272, which means analysts expect the stock to increase by 891.69% over the next twelve months. That average ranking earns C4 Therapeutics Inc an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CCCC a Buy today. Find out what this means to you and get the rest of the rankings on CCCC!